AbbVie Reports Third-Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
AbbVie (ABBV) Falls Following Q3 Release - Softness in US Sales Likely to 'Raise Concerns'
October 28, 2022 9:53 AM EDTAbbVie (NYSE: ABBV) shares are down more than 5% in early Friday trading after the company reported third-quarter earnings before the open, missing revenue expectations.
The company reported earnings of $3.66 per share, $0.08 better than the analyst estimate of $3.58, while revenue for the quarter came in at $14.81 billion versus the consensus estimate of $14.93 billion.
Following the report, Mizuho Securities analyst Uy Ear told investors in a note... More
AbbVie (ABBV) Raises Quarterly Dividend 5% to $1.48; 3.9% Yield
October 28, 2022 7:47 AM EDTAbbVie (NYSE: ABBV) declared a quarterly dividend of $1.48 per share, or $5.92 annualized. This is a 5% increase from the prior dividend of $1.41.
The dividend will be payable on February 15, 2023, to stockholders of record on January 13, 2023, with an ex-dividend date of January 12,... More
AbbVie (ABBV) Tops Q3 EPS by 8c, Updates FY EPS Guidance
October 28, 2022 7:45 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $3.66, $0.08 better than the analyst estimate of $3.58. Revenue for the quarter came in at $14.81 billion versus the consensus estimate of $14.93 billion.
GUIDANCE:
AbbVie sees FY2022 EPS of $13.84-$13.88, versus the consensus of $13.86.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More